WallStSmart

Jyong Biotech Ltd. Ordinary Shares (MENS)vsModerna Inc (MRNA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

MENS leads profitability with a 0.0% profit margin vs -110.5%. MRNA earns a higher WallStSmart Score of 31/100 (F).

MENS

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: -4.07

MRNA

Avoid

31

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MENS.

MRNAUndervalued (+73.1%)

Margin of Safety

+73.1%

Fair Value

$150.76

Current Price

$215.27

$64.51 discount

UndervaluedFair: $150.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MENS1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.7410/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 8.5/10
Market CapQuality
$101.49B9/10

Large-cap with strong market position

Revenue GrowthGrowth
29.2%8/10

Revenue surging 29.2% year-over-year

Areas to Watch

MENS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$140.65M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

MRNA4 concerns · Avg: 2.8/10
Price/BookValuation
12.7x4/10

Trading at 12.7x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-40.8%2/10

ROE of -40.8% — below average capital efficiency

EPS GrowthGrowth
-85.1%2/10

Earnings declined 85.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : MENS

The strongest argument for MENS centers on Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.

Bear Case : MENS

The primary concerns for MENS are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MENS profiles as a value stock while MRNA is a growth play — different risk/reward profiles.

MRNA is growing revenue faster at 29.2% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRNA scores higher overall (31/100 vs 17/100) and 29.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Jyong Biotech Ltd. Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Jyong Biotech Ltd. (ticker: MENS) is a pioneering biotechnology firm focused on developing transformative therapeutic solutions for cancer and autoimmune diseases. Leveraging its expertise in genomics and molecular biology, the company has built a promising pipeline of innovative treatments supported by a formidable intellectual property portfolio. By establishing strategic partnerships within the biopharmaceutical sphere, Jyong Biotech is well-positioned to capitalize on emerging market opportunities, all while emphasizing scientific excellence and a patient-centered approach that enhances its standing in the healthcare innovation arena.

Visit Website →

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?